The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  Nakaigawa, Noboru ^a   Kondo, Keiichi ^a   Ueno, Daiki ^a   Namura, Kazuhiro ^a   Makiyama, Kazuhide ^a   Kobayashi, Kazuki ^b   Shioi, Koichi ^b   Ikeda, Ichiro ^c   Kishida, Takeshi ^d   Kaneta, Tomohiro ^a   Minamimoto, Ryogo ^a   Tateishi, Ukihide ^a   Inoue, Tomio ^a   Yao, Masahiro ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOSUKA KYOSAI HOSPITAL   (Japan)

^c Yokohama Minami Kyosai Hospital   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

Author keywords

FDG PET CT; Renal cell carcinoma; Resistance acquisition; Standardized uptake value; Tyrosine kinase inhibitor

Indexed keywords

CYTOKINE; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; GLUCOSE; PROTEIN KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE INTAKE; HUMAN; HYPOXIA; IN VITRO STUDY; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; NEPHRECTOMY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; CANCER STAGING; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DIAGNOSTIC IMAGING; FOLLOW UP; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; RADIOPHARMACEUTICALS; SURVIVAL RATE;

EID: 85008455046     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-3044-0     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell carcinoma in the United States. JAMA. 1999;281:1628-31.
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843-52.
4. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-75.
5. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma: Groupe Français D'Immunotherapie. N Engl J Med. 1998;338:1272-8.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115-24.
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med. 2007;356:125-34.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-90.
9. Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, et al. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18 F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010;10:667.
10. Nakaigawa N, Kondo K, Tateishi U, Minamimoto R, Kaneta T, Namura K, et al. FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. BMC Cancer. 2016;16:67.
11. Ueno D, Yao M, Tateishi U, Minamioto R, Makiyama K, Hayashi N, et al. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer. 2012;12:162.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
13. Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun. 2009;30:519-24.
14. Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, et al. 18 F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009;24:137-44.
15. Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res. 2011;17:6021-8.
16. Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, et al. Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol. 2013;63:244-51.
17. Linehan WM, Rouault TA. Molecular pathways: fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. Clin Cancer Res. 2013;19:3345-52.
18. Jiménez-Valerio G, Martínez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suárez C, et al. Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients. Cell Rep. 2016;15(6):1134-43.
19. Allen E, Miéville P, Warren CM, Saghafinia S, Li L, Peng MW, Hanahan D. Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep. 2016;15(6):1144-60.
20. Pisarsky L, Bill R, Fagiani E, Dimeloe S, Goosen RW, Hagmann J, Hess C, Christofori G. Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep. 2016;15(6):1161-74.
21. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603.
22. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-92.